Supernus Pharmaceuticals Financial Statements
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Supernus Pharmaceuticals revenue and earnings
In fiscal 2025, Supernus Pharmaceuticals generated $719.0 million in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Supernus Pharmaceuticals reported a net loss of $38.5 million, compared with net income of $73.9 million a year earlier. Gross margin was 89.6% (up from 88.2%) and operating margin -8.7%.
Diluted earnings per share came in at -$0.68, down from $1.32. Over the last 5 fiscal years, SUPN's revenue has grown at a 6.7% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Supernus Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 718.95M | 661.82M | 607.52M | 667.24M | 579.77M | 520.40M | 392.75M | 408.90M | 302.24M | 215.00M |
| Revenue growth (YoY) | +8.63% | +8.94% | -8.95% | +15.09% | +11.41% | +32.50% | -3.95% | +35.29% | +40.57% | +45.80% |
| Cost of Revenue | 74.56M | 77.91M | 83.78M | 87.22M | 75.06M | 52.46M | 16.66M | 15.36M | 15.21M | 11.99M |
| Gross Profit | 644.39M | 583.91M | 523.74M | 580.02M | 504.71M | 467.94M | 376.10M | 393.54M | 287.02M | 203.02M |
| Operating Expenses | 706.67M | 502.25M | 529.01M | 533.89M | 418.69M | 294.24M | 227.52M | 249.10M | 187.48M | 148.80M |
| Research & Development | 106.23M | 108.80M | 91.59M | 74.55M | 90.47M | 75.96M | 69.10M | 89.21M | 49.58M | 42.79M |
| Selling, General & Admin | 485.56M | 321.58M | 336.36M | 377.22M | 304.76M | 200.68M | 153.25M | 154.70M | 137.91M | 106.01M |
| Operating Income | -62.28M | 81.67M | -5.27M | 46.12M | 86.03M | 173.70M | 148.57M | 144.44M | 99.54M | 54.22M |
| Interest Expense | 0 | 0 | 2.42M | 7.07M | 19.70M | 19.43M | 18.21M | 13.84M | 134.00K | 543.00K |
| Other Income (Expense) | 13.25M | 16.20M | 8.04M | 14.62M | -12.85M | -5.05M | -1.08M | -4.27M | 1.08M | -3.85M |
| Pretax Income | -49.03M | 97.87M | 2.77M | 60.74M | 73.17M | 168.65M | 147.49M | 140.18M | 100.62M | 50.37M |
| Income Tax | -10.48M | 24.00M | 1.45M | 32.00K | 19.75M | 41.70M | 34.43M | 29.18M | 43.33M | -40.85M |
| Net Income | -38.55M | 73.86M | 1.32M | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M | 57.28M | 91.22M |
| Net Income growth (YoY) | -152.19% | +5512.84% | -97.83% | +13.64% | -57.92% | +12.29% | +1.86% | +93.76% | -37.20% | +554.20% |
| EPS (Basic) | -0.68 | 1.34 | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 |
| EPS (Diluted) | -0.68 | 1.32 | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 | 2.05 | 1.08 | 1.76 |
| Shares Outstanding (Basic) | 56.45M | 55.10M | 54.54M | 53.67M | 53.10M | 52.62M | 52.41M | 51.99M | 50.76M | 49.47M |
| Shares Outstanding (Diluted) | 56.45M | 55.96M | 55.51M | 61.68M | 54.36M | 53.69M | 53.82M | 54.10M | 53.30M | 51.71M |
| EBITDA | 29.28M | 162.08M | 79.59M | 131.67M | 118.62M | 191.84M | 155.23M | 151.51M | 107.67M | 56.62M |
| Gross Margin | 89.63% | 88.23% | 86.21% | 86.93% | 87.05% | 89.92% | 95.76% | 96.24% | 94.97% | 94.43% |
| Operating Margin | -8.66% | 12.34% | -87.00% | 6.91% | 14.84% | 33.38% | 37.83% | 35.33% | 32.93% | 25.22% |
| Net Margin | -5.36% | 11.16% | 22.00% | 9.10% | 9.21% | 24.39% | 28.79% | 27.14% | 18.95% | 42.43% |
This table shows 10 annual periods of Supernus Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow SUPN's reporting calendar. What is a income statement?